This is a Phase 1b/2a, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 in combination with atezolizumab administered to patients with advanced solid tumors (Part 1) and patients with Platinum-resistant Ovarian Cancer (Part 2)

开始日期2023-09-15

申办/合作机构

Sonnet BioTherapeutics, Inc.

[+1]

NCT05408572

/ Completed早期临床1期

A Phase 1, Randomized, Adaptive-Design, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-1010 (IL12-FHAB) in Healthy Adults

SB102 is a randomized, double-blind, single center, placebo-controlled study in healthy adults starting with sentinel participants at each dose level to carefully assess the safety, tolerability, PK, and PD of SON-1010.

开始日期2022-07-27

申办/合作机构

Sonnet BioTherapeutics, Inc.

NCT05352750

/ Unknown status临床1期

A Phase 1, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SON-1010 (IL12-FHAB) in Adult Patients With Advanced Solid Tumors.

This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.

开始日期2022-04-20

申办/合作机构

Sonnet BioTherapeutics, Inc.

100 项与 SON-1010 相关的临床结果

登录后查看更多信息

100 项与 SON-1010 相关的转化医学

登录后查看更多信息

100 项与 SON-1010 相关的专利（医药）

登录后查看更多信息

项与 SON-1010 相关的文献（医药）

Frontiers in immunology

A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers

Article

作者: Cini, John K ; Kuan, Isabelle ; Lickliter, Jason ; Ryan, Philip J ; Polasek, Thomas M ; Chawla, Sant P ; Kenney, Richard T ; Dexter, Susan ; DaFonseca, Manuel ; Bingham, Justus

Background:

The benefits of recombinant interleukin-12 (rIL-12) as a multifunctional cytokine and potential immunotherapy for cancer have been sought for decades based on its efficacy in multiple mouse models. Unexpected toxicity in the first phase 2 study required careful attention to revised dosing strategies. Despite some signs of efficacy since then, most rIL-12 clinical trials have encountered hurdles such as short terminal elimination half-life (T½), limited tumor microenvironment targeting, and substantial systemic toxicity. We developed a strategy to extend the rIL-12 T½ that depends on binding albumin in vivo to target tumor tissue, using single-chain rIL-12 linked to a fully human albumin binding (FHAB) domain (SON-1010). After initiating a dose-escalation trial in patients with cancer (SB101), a randomized, double-blind, placebo-controlled, single-ascending dose (SAD) phase 1 trial in healthy volunteers (SB102) was conducted.

Methods:

SB102 (NCT05408572) focused on safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) endpoints. SON-1010 at 50-300 ng/kg or placebo administered subcutaneously on day 1 was studied at a ratio of 6:2, starting with two sentinels; participants were followed through day 29. Safety was reviewed after day 22, before enrolling the next cohort. A non-compartmental analysis of PK was performed and correlations with the PD results were explored, along with a comparison of the SON-1010 PK profile in SB101.

Results:

Participants receiving SON-1010 at 100 ng/kg or higher tolerated the injection but generally experienced more treatment-emergent adverse effects (TEAEs) than those receiving the lowest dose. All TEAEs were transient and no other dose relationship was noted. As expected with rIL-12, initial decreases in neutrophils and lymphocytes returned to baseline by days 9-11. PK analysis showed two-compartment elimination in SB102 with mean T½ of 104 h, compared with one-compartment elimination in SB101, which correlated with prolonged but controlled and dose-related increases in interferon-gamma (IFNγ). There was no evidence of cytokine release syndrome based on minimal participant symptoms and responses observed with other cytokines.

Conclusion:

SON-1010, a novel presentation for rIL-12, was safe and well-tolerated in healthy volunteers up to 300 ng/kg. Its extended half-life leads to a prolonged but controlled IFNγ response, which may be important for tumor control in patients.

Clinical trial registration:

https://clinicaltrials.gov/study/NCT05408572, identifier NCT05408572.

Frontiers in Immunology

SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy

Article

作者: McAndrew, Stephen J ; Cini, John K ; Boohaker, Rebecca ; Lapi, Suzanne E ; Brody, Rich ; Eraslan, Rukiye-Nazan ; Mohan, Pankaj ; Kenney, Richard T ; Dexter, Susan ; Rezac, Darrel J

Background:

Cytokines have been promising cancer immunotherapeutics for decades, yet only two are licensed to date. Interleukin-12 (IL-12) is a potent regulator of cell-mediated immunity that activates NK cells and interferon-γ (IFNγ) production. It plays a central role in multiple pathways that can enhance cancer cell death and modify the tumor microenvironment (TME). Attempts to dose rIL-12 were initially successful but IFNγ toxicity in Phase 2 complicated further development in the late 1990s. Since then, better dosing strategies have been developed, but none have achieved the level of cancer control seen in preclinical models. We set out to develop a novel strategy to deliver fully functional IL-12 and other biologics to the TME by binding albumin, taking advantage of its ability to be concentrated and retained in the tumor.

Methods:

Single-chain variable fragments (scFv) were identified from a human phage display library that bound human, mouse, and cynomolgus macaque serum albumin, both at physiologic and acidic conditions. These were taken through a series of steps to identify strongly binding molecules that don’t interfere with the normal physiology of albumin to bind FcRn, giving it prolonged half-life in serum, along with SPARC/GP60, which allows albumin to target the TME. A final molecule was chosen and a single mutation was made that minimizes the potential for immunogenicity. This fully human albumin-binding (FHAB®) domain was characterized and manufacturing processes were developed to bring the first drug candidate into the clinic.

Results:

Once identified, the murine form of mIL12-FHAB was studied preclinically to understand its mechanism of action and biodistribution. It was found to be much more efficient at blocking tumor growth compared to murine IL-12, while stimulating significant IFNγ production with minimal toxicity. SON-1010, which uses the human IL-12 sequence, passed through all of the characterization and required toxicology and is currently being studied in the clinic.

Conclusions:

We identified and developed a platform technology with prolonged half-life that can target IL-12 and other immune modulators to the TME. Safety and efficacy are being studied using SON-1010 as monotherapy and in combination with checkpoint blockade strategies.

项与 SON-1010 相关的新闻（医药）

2025-10-15

·GlobeNewswire-Health Care

Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma

HOUSTON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) is collaborating with Spanios on a non-clinical study using New Alternate Methodologies (NAM)-based patient-derived tumoroid (PDT) platforms that emulate the tumor microenvironment (TME) ex vivo to evaluate the effect of SON-1010 (IL-12-FHAB) in soft tissue sarcoma. The study aims to speed up the development of treatments for patients with rare and difficult-to-treat cancers. This study utilizes Spanios’ advanced patient-derived tumoroid COMPASS platform, which is engineered to closely replicate the TME, along with physiological oxygenation that can influence cancer progression and treatment response. In contrast to conventional preclinical models—often based on animal testing and less representative of human biology—patient-derived tumoroids preserve the distinct genetic and environmental attributes of individual tumors. By replicating the different pH and oxygen concentrations ex-vivo, using our COMPASS platform with our NAM-based methodology, we seek to enhance the understanding of SON-1010’s efficacy against cancer cells. This approach is anticipated to yield more accurate and dependable predictions regarding the clinical performance of SON-1010 therapy. Through the integration of these innovative techniques, Sonnet intends to expedite the development of effective therapies for multiple rare and difficult-to-treat cancers, ultimately providing new options for patients with limited treatment paradigms. “We wanted to try this innovative approach that evaluates physiologically relevant tumoroids,” said Raghu Rao, PhD, Sonnet’s Interim CEO, “to see how SON-1010 might impact the organoid growth and other readouts. This platform has the potential to be used with any type of solid tumor for rapid evaluation of the effects of new drugs and combinations.” About Sonnet Bio Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin-Binding), the Company’s technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to the TME. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines. For additional information about Sonnet, please visit Sonnet BioTherapeutics, Inc. (SONN). Bhuvanesh Dave, PhD, Co-Founder and CEO of Spanios noted, “We are excited to collaborate with the uniquely insightful and developmentally effective team at Sonnet to advance therapeutic research for solid tumors. By combining our expertise, resources, and innovative platforms, we continue to deliver on our mission of identifying, discovering, and delivering effective treatments to rare and difficult to treat cancer indications.” About Spanios Spanios was established with the objective of accelerating the discovery, identification, and development of oncology drugs for rare and challenging cancers. By enabling the ex-vivo recreation of human solid tumors and their microenvironment, Spanios eliminates reliance on traditional animal models that often lack predictive accuracy. In response to the dynamic requirements of onco-therapeutic research, Spanios has developed the proprietary patient-derived tumoroid (PDT) platform, COMPASS (Custom Organoid Modelling Platform for Accurate and Speedy Solutions). This robust set of models offers reliable clinical outcome prediction through precision-focused preclinical research. The three tiers of COMPASS, each relevant to human biology and translation, expedite drug discovery by prioritizing efficacy. For additional information about Spanios, please visit www.spanioslab.com. Bhuvanesh Dave, PhD; Co-Founder & CEO, bhuvanesh.dave@spanioslab.com www.spanioslab.com

临床1期

2025-05-01

·sonnetbio.com

Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit

PRINCETON, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeting the tumor microenvironment (TME), today announced it will present at the 6th Annual Cytokine-Based Drug Development Summit being held May 15-16, 2025 in Boston, MA. Details of the presentation are as follows: Title: Managing Toxicity Caused by The Over Expression of Cytokines to Widen the Therapeutic Window Session: Understanding Toxicity Challenges & Improving Safety Profiles to Widen the Therapeutic Window Speaker: Richard Kenney, M.D., Chief Medical Officer of Sonnet Date and Time: Thursday, May 15, 2025 at 11:15 AM ET As part of the session, Dr. Kenney will discuss: Exploring the strategy behind the introduction of receptor bias to reduce toxicity and improve efficacy; Key strategies for optimizing cytokine potency and mitigating their inherent toxicity while considering the role of the therapeutic index in determining the clinical efficacy and safety of cytokine-based therapies; and Examining whether toxicity is the primary limiting factor in achieving therapeutic benefit and considering alternative factors that may influence the ‘therapeutic window’. For more information, please visit the Summit website here. About Sonnet BioTherapeutics Holdings, Inc. Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin-Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines. Sonnet’s lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors, certain types of sarcoma, and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study through a Master Clinical Trial and Supply Agreement, along with ancillary Quality and Safety Agreements, with Roche in combination with atezolizumab (Tecentriq®) for the treatment of platinum-resistant ovarian cancer (PROC) (NCT05756907). The Company is also evaluating its second program using this platform, SON-1210, an IL12-FHAB-IL15 for solid tumors, in collaboration with the Sarcoma Oncology Center to commence an investigator-initiated and funded Phase 1/2a study for the treatment of pancreatic cancer. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the outcome of the Company’s clinical trials, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investor Relations Contact: JTC Team, LLC Jenene Thomas 908-824-0775 SONN@jtcir.com Released May 1, 2025

免疫疗法

2025-04-16

·sonnetbio.com

Sonnet Releases Virtual Investor "What This Means" Segment

- Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, of Sonnet discuss the recently announced safety data related to SON-1010 - Watch the "What This Means" video here PRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced that members of the Sonnet management team participated in a Virtual Investor "What This Means" segment. As part of the segment, Raghu Rao, Interim Chief Executive Officer and Dr. Richard Kenney, Chief Medical Officer, discussed the recently announced positive safety results of SON-1010 (IL12-FHAB) at the highest dose combined with atezolizumab being evaluated in the Phase 1b/2a clinical trial in adult patients with advanced solid tumors or platinum-resistant ovarian cancer (PROC) (the SB221 study). Mr. Rao and Dr. Kenney also provided insight into next steps for the program. The Virtual Investor "What This Means" segment featuring Sonnet is now available here. About Sonnet BioTherapeutics Holdings, Inc. Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin-Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the safety and efficacy of immune modulating biologic drugs. FHAB platform is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines. Sonnet’s lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors, certain types of sarcoma, and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study through a Master Clinical Trial and Supply Agreement, along with ancillary Quality and Safety Agreements, with Roche in combination with atezolizumab (Tecentriq®) for the treatment of platinum-resistant ovarian cancer (PROC) (NCT05756907). The Company is also evaluating its second program using this platform, SON-1210, an IL12-FHAB-IL15 for solid tumors, in collaboration with the Sarcoma Oncology Center to commence an investigator-initiated and funded Phase 1/2a study for the treatment of pancreatic cancer. Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the outcome of the Company’s clinical trials, the Company's cash runway, the Company's product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investor Relations Contact: JTC Team, LLC Jenene Thomas 908-824-0775 SONN@jtcir.com Released April 16, 2025

免疫疗法临床研究

100 项与 SON-1010 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
晚期恶性实体瘤	临床2期	美国	Sonnet BioTherapeutics, Inc.	2023-09-15
晚期恶性实体瘤	临床2期	美国	Hoffmann-La Roche Ltd.	2023-09-15
晚期恶性实体瘤	临床2期	澳大利亚	Sonnet BioTherapeutics, Inc.	2023-09-15
晚期恶性实体瘤	临床2期	澳大利亚	Hoffmann-La Roche Ltd.	2023-09-15
铂耐药性卵巢癌	临床2期	美国	Hoffmann-La Roche Ltd.	2023-09-15
铂耐药性卵巢癌	临床2期	美国	Sonnet BioTherapeutics, Inc.	2023-09-15
铂耐药性卵巢癌	临床2期	澳大利亚	Hoffmann-La Roche Ltd.	2023-09-15
铂耐药性卵巢癌	临床2期	澳大利亚	Sonnet BioTherapeutics, Inc.	2023-09-15
软组织肉瘤	临床1期	美国	Sonnet BioTherapeutics, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05352750 (SB101, ESMO2025)	临床1期	软组织肉瘤	20	SON-1010	窪衊鹹壓糧遞積築廠鹽(窪築醖鏇觸範鑰築壓構) = 廠衊餘糧範糧簾繭醖築願淵構鹽製襯鹹糧鏇顧 (觸憲網鑰鬱願膚醖遞餘 ) 更多	积极	2025-10-17
NCT05352750 (SB101, ESMO2025)	临床1期	软组织肉瘤	20	SON-1010 + Trabectedin	窪衊鹹壓糧遞積築廠鹽(窪築醖鏇觸範鑰築壓構) = 構選構鹹鹹艱鬱顧選遞願淵構鹽製襯鹹糧鏇顧 (觸憲網鑰鬱願膚醖遞餘 ) 更多	积极	2025-10-17
NCT05352750 (SB101, GlobeNewswire \| Company_Website) 人工标引	临床1期	实体瘤	24	SON-1010	製膚遞夢顧襯鬱廠願衊(蓋鏇觸網製願獵糧壓製) = 壓餘蓋鹹淵廠膚憲鬱艱簾築夢襯鑰淵鹽膚構願 (積齋蓋鹽遞糧積廠鹹選 ) 更多	积极	2024-12-09
SB101 (NEWS)	N/A	卵巢上皮癌	61	SON-1010	糧積網衊淵製餘壓選醖(夢蓋繭遞簾窪餘築膚鹽) = 選積製鏇顧淵衊鏇積願鹽壓鹽膚廠醖醖鑰鑰醖 (網蓋選觸壓顧蓋糧齋廠 )	积极	2024-05-20
SB101 (NEWS)	N/A	卵巢上皮癌	61	SON-1010+阿替利珠单抗	-	积极	2024-05-20
NCT05408572 (SB102, Literature \| Pubmed \| Front Immunol) 人工标引	临床1期	-	-	SON-1010	憲衊構鑰鑰繭鹹鹹獵範(襯廠簾鹹夢窪衊鏇淵鬱) = two-compartment elimination in SB102 with mean T½ of 104 h, compared with one-compartment elimination in SB101 選廠網壓鬱鬱齋鑰衊選 (壓範糧壓壓鹽願憲願廠 )	积极	2024-02-29
AACR2023 人工标引	N/A	HR阳性/HER2低表达实体瘤	11	SON-1010	壓繭蓋壓繭製壓鹽鑰窪(簾願壓淵遞廠餘鏇願齋) = 選遞願網積醖淵糧鬱鑰鹽築鏇糧醖淵簾積觸選 (壓壓衊糧蓋積簾構鹹齋 ) 更多	积极	2023-04-14
AACR2023 人工标引	N/A	HR阳性/HER2低表达实体瘤	11	SON-1010 (the first 3 dose cohorts)	窪鬱繭糧遞窪鑰鹹鏇齋(衊壓淵鏇鹽繭積顧憲膚) = 願憲遞糧鏇鏇鬱鑰觸鹽鑰網積襯襯衊顧選糧餘 (醖鹹範網鏇壓壓顧鹹鑰 )	积极	2023-04-14
NCT05352750 (SB101, Corporate Publications) 人工标引	临床1期	肿瘤	12	SON-1010	鏇餘網膚憲鑰鬱願衊獵(繭艱憲構餘遞艱構餘餘) = mild/moderate, transient in nature, and have all been tolerable 願襯醖鹽遞網膚製觸艱 (製顧範獵膚醖齋醖網鬱 )	积极	2022-11-02